| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institute of Endocrine Sciences (S.C., V.C., A.L., P.B.-P., A.S.) and Department of Medical Sciences (M.P.), Ospedale Maggiore IRCCS, and Pathology Unit (E.L., L.V.), Department of Clinical Sciences, Ospedale L. Sacco, University of Milan, 20122 Milan, Italy
Address all correspondence and requests for reprints to: Anna Spada, M.D., Institute of Endocrine Sciences, Via F.Sforza, 35, 20122 Milan, Italy. E-mail: anna.spada{at}unimi.it.
Ghrelin is a novel gastrointestinal hormone involved in several metabolic functions. Although the expression of ghrelin has been demonstrated in most gastrointestinal carcinoids and pancreatic tumors, the circulating levels of this peptide have been marginally assessed in patients with these disorders. We measured plasma ghrelin levels in 16 patients with gastrointestinal carcinoid (10 with midgut and 6 with gastric carcinoid), 24 patients with pancreatic tumor (8 with gastrinoma, 2 with insulinoma, 2 with vipoma, 1 with glucagonoma, and 11 with nonfunctioning tumor), and 35 healthy controls. Plasma ghrelin levels recorded in patients with gastroenteropancreatic tumors were similar to controls (mean ± SE, 182.7 ± 66.5 pM in patients vs. 329 ± 32 pM in controls, P = not significant), and no significant difference between gastrointestinal and pancreatic, functioning and nonfunctioning, and metastatic and nonmetastatic tumors was observed. One patient with metastatic nonfunctioning pancreatic tumor had circulating ghrelin levels of 12,000 pM that were slightly reduced during chemotherapy and interferon therapy. Immunohistochemistry performed on peritoneal lesions showed an intense, focal cytoplasmic positivity for ghrelin. Despite the 50-fold increase in ghrelin concentrations, the patient had normal serum GH and IGF-I levels. In conclusion, the study showed that carcinoids and pancreatic tumors rarely cause ghrelin hypersecretion. However, in this series, 1 pancreatic ghrelinoma not associated with clinical features of acromegaly was identified.
This work was supported in part by MURST Grant 2002068252 and Ricerca Corrente Funds of Ospedale Maggiore IRCCS.
Abbreviations: CgA, Chromogranin A; nv, normal value; PP, pancreatic polypeptide.
This article has been cited by other articles:
 |
|
 |
|
  N. Alonso, M. L. Granada, I. Salinas, J. L. Reverter, L. Flores, I. Ojanguren, E. M. Martinez-Caceres, and A. Sanmarti Plasma ghrelin concentrations in type 1 diabetic patients with autoimmune atrophic gastritis Eur. J. Endocrinol., December 1, 2007; 157(6): 763 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mottershead, E. Karteris, J. Y Barclay, S. Suortamo, M. Newbold, H. Randeva, and C. U Nwokolo Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma J. Clin. Pathol., April 1, 2007; 60(4): 405 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ekeblad, B. Nilsson, M. H. Lejonklou, T. Johansson, P. Stalberg, O. Nilsson, H. Ahlman, and B. Skogseid Gastrointestinal stromal tumors express the orexigen ghrelin. Endocr. Relat. Cancer, September 1, 2006; 13(3): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. D. Dixit, A. T. Weeraratna, H. Yang, D. Bertak, A. Cooper-Jenkins, G. J. Riggins, C. G. Eberhart, and D. D. Taub Ghrelin and the Growth Hormone Secretagogue Receptor Constitute a Novel Autocrine Pathway in Astrocytoma Motility J. Biol. Chem., June 16, 2006; 281(24): 16681 - 16690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P L Jeffery, R E Murray, A H Yeh, J F McNamara, R P Duncan, G D Francis, A C Herington, and L K Chopin Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines Endocr. Relat. Cancer, December 1, 2005; 12(4): 839 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P Silva, K. Bethmann, F. Raulf, and H. A Schmid Regulation of ghrelin secretion by somatostatin analogs in rats Eur. J. Endocrinol., June 1, 2005; 152(6): 887 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Avram, C. A. Jaffe, K. V. Symons, and A. L. Barkan Endogenous Circulating Ghrelin Does Not Mediate Growth Hormone Rhythmicity or Response to Fasting J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2982 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kojima and K. Kangawa Ghrelin: Structure and Function Physiol Rev, April 1, 2005; 85(2): 495 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Piaditis, A. Angellou, G. Kontogeorgos, N. Mazarakis, T. Kounadi, G. Kaltsas, K. Vamvakidis, R. V. Lloyd, E. Horvath, and K. Kovacs Ectopic Bioactive Luteinizing Hormone Secretion by a Pancreatic Endocrine Tumor, Manifested as Luteinized Granulosa-Thecal Cell Tumor of the Ovaries J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2097 - 2103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rindi, A. Torsello, V. Locatelli, and E. Solcia Ghrelin Expression and Actions: A Novel Peptide for an Old Cell Type of the Diffuse Endocrine System Experimental Biology and Medicine, November 1, 2004; 229(10): 1007 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Tsolakis, G. M. Portela-Gomes, M. Stridsberg, L. Grimelius, A. Sundin, B. K. Eriksson, K. E. Oberg, and E. T. Janson Malignant Gastric Ghrelinoma with Hyperghrelinemia J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3739 - 3744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
